Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma.

ABSTRACT: The treatment landscape for lymphoma and multiple myeloma, which disproportionally affect older adults, has been transformed by the advent of T cell-mediated immunotherapies, including immune checkpoint inhibition, T cell-engaging bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, during the last decade. These treatment modalities re-enable the patient's own immune system to combat malignant cells and offer the potential for sustained remissions and cure for various diseases.Age profoundly affects the physiological function of the immune system. The process of biological aging is largely driven by inflammatory signaling, which is reciprocally fueled by aging-related alterations of physiology and metabolism. In the T cell compartment, aging contributes to T cell sene

SUBMITTER: Ullrich F 

PROVIDER: S-EPMC11624774 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature